The 3rd quarter edition of our ReMarks newsletter is out, including:
- Supreme Court decision on Actavis v Eli Lilly (Doctrine of Equivalents)
- Working with the new EU Trade Mark Regulation
- Brexit: A first look at the UK's EU Withdrawal Bill's implications for IP
- New PPH program between Malaysia and EPO
- Brexit: European Commission publishes position paper on IPRs
- Canadian Federal Court of Appeal Indicates that a "Promise" is not the Solution
- The "plausibility" requirement at the EPO
- Warner-Lambert's pain continues in Singapore
- EPO engages with Unitary Patents
To view the full article please click here.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.